S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis

키워드

참고문헌 (55)

1. Andersson AK, "Recent developments in the immunobiology of rheumatoid arthritis", Arthritis Res Ther, 10, pp.204~ (2008)
2. Huber LC, "Synovial fibroblasts: key players in rheumatoid arthritis", Rheumatology (Oxford), 45, pp.669~675 (2006)
3. McInnes IB, "Cytokines in the pathogenesis of rheumatoid arthritis", Nat Rev Immunol, 7, pp.429~442 (2007)
4. 박성환, "류마티스 관절염의 새로운 진단법", 대한내과학회지, 76(1), pp.7~11 (2009), 대한내과학회
5. Park SH, "Guideline for treatment or rheumatoid arthritis", Korean J Med, 79, pp.s455~s458 (2010)
6. Leclerc E, "Binding of S100 proteins to RAGE: an update", Biochim Biophys Acta, 1793, pp.993~1007 (2009)
7. Vogl T, "Mrp8 and Mrp14are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock", Nat Med, 13, pp.1042~1049 (2007)
8. Berntzen HB, "A longitudinal study of the leukocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis", J Rheumatol, 16, pp.1416~1420 (1989)
9. Brun JG, "Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity", J Rheumatol, 19, pp.859~862 (1992)
10. Brun JG, "Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases", J Rheumatol, 21, pp.733~738 (1994)
11. Bakker MF, "Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study", Ann Rheum Dis, 71, pp.1692~1697 (2012)
12. Dale I, "Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes: immunof luorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin", Am J Clin Pathol, 84, pp.24~34 (1985)
13. Foell D, "Proinf lammatory S100 proteins in arthritis and autoimmune disease", Arthritis Rheum, 50, pp.3762~3771 (2004)
14. Fagerhol MK, "A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells", Bull Eur Physiopathol Respir, 16(Suppl), pp.273~282 (1980)
15. Edgeworth J, "Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells", J Biol Chem, 266, pp.7706~7713 (1991)
16. Wolf R, "Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15", J Immunol, 181, pp.1499~1506 (2008)
17. Ehrchen JM, "The endogenous Toll-like receptor 4 agonist S100A8", S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer, 2009, pp.86, 557~566
18. Bianchi ME, "DAMPs, PAMPs and alarmins: all we need to know about danger", J Leukoc Biol, 81, pp.1~5 (2007)
19. Foell D, "S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules", J Leukoc Biol, 81, pp.28~37 (2007)
20. Foell D, "Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis", Nat Clin Pract Rheumatol, 3, pp.382~390 (2007)
21. Rammes A, "Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway", J Biol Chem, 272, pp.9496~9502 (1997)
22. Ghavami S, "S100A8", A9at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway, 2008, pp.83, 1484~1492
23. Tamaki Y, "Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis", J Rheumatol, 38, pp.810~820 (2011)
24. Malemud CJ, "Myeloid-related protein activity in rheumatoid arthritis", Int J Inflam, 2011, pp.580295~ (2011)
25. Goh FG, "Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis", Rheumatology (Oxford), 51, pp.7~23 (2012)
26. Frosch M, "Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis", Arthritis Rheum, 43, pp.628~637 (2000)
27. Johne B, "Functional and clinical aspects of the myelomonocyte protein calprotectin", Mol Pathol, 50, pp.113~123 (1997)
28. Loser K, "The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells", Nat Med, 16, pp.713~717 (2010)
29. Liao H, "Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial f luid and serum of patients with rheumatoid arthritis", Arthritis Rheum, 50, pp.3792~3803 (2004)
30. Sunahori K, "The S100A8", A9 heterodimer amplifies proinf lammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis, 2006, pp.8, R69~
31. Hammer HB, "Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis", Scand J Rheumatol, 37, pp.179~182 (2008)
32. Pap T, "Fibroblast biology:role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis", Arthritis Res, 2, pp.361~367 (2000)
33. Baillet A, "Synovial f luid proteomic f ingerprint: S100A8, S100A9 and S100A12proteins discriminate rheumatoid arthritis from other inf lammatory joint diseases", Rheumatology (Oxford), 49, pp.671~682 (2010)
34. Youssef P, "Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8", 14 heterodimer in rheumatoid arthritis synovial membrane, 1999, pp.26, 2523~2528
35. 이동건, "MRP8 promotes Th17 differentiation via upregulation of IL-6 production by fibroblast-like synoviocytes in rheumatoid arthritis", Experimental and Molecular Medicine, 45(4), pp.1~9 (2013), 생화학분자생물학회
36. Dale I, "Purif ication and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen", Eur J Biochem, 134, pp.1~6 (1983)
37. Hammer HB, "Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inf lammation and damage in rheumatoid arthritis", Ann Rheum Dis, 66, pp.1093~1097 (2007)
38. Andres Cerezo L, "Decreases in serum levels of S100A8", 9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis, 2011, pp.13, R122~
39. Hammer HB, "The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab", Arthritis Res Ther, 13, pp.R178~ (2011)
40. Odegard S, "Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients", Arthritis Rheum, 54, pp.68~75 (2006)
41. Jansen LM, "Predictors of radiographic joint damage in patients with early rheumatoid arthritis", Ann Rheum Dis, 60, pp.924~927 (2001)
42. Jansen LM, "The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis", J Rheumatol, 30, pp.1691~1695 (2003)
43. Hammer HB, "Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis", Ann Rheum Dis, 69, pp.150~154 (2010)
44. Mease PJ, "Improving the routine management of rheumatoid arthritis: the value of tight control", J Rheumatol, 37, pp.1570~1578 (2010)
45. Verstappen SM, "Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission: Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)", Ann Rheum Dis, 66, pp.1443~1449 (2007)
46. Bakker MF, "Tight control in the treatment of rheumatoid arthritis:efficacy and feasibility", Ann Rheum Dis, 66(Suppl 3), pp.iii56~iii60 (2007)
47. Smolen JS, "Treating rheumatoid arthritis to target: recommendations of an international task force", Ann Rheum Dis, 69, pp.631~637 (2010)
48. Prevoo ML, "Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis", Arthritis Rheum, 38, pp.44~48 (1995)
49. Aletaha D, "The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI)to monitor patients in standard clinical care", Best Pract Res Clin Rheumatol, 21, pp.663~675 (2007)
50. Uhlig T, "Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis", Ann Rheum Dis, 68, pp.972~975 (2009)
51. Thompson PW, "Comparison of four articular indices for use in clinical trials in rheumatoid arthritis:patient, order and observer variation", J Rheumatol, 18, pp.661~665 (1991)
52. Pincus T, "The American College of Rheumatology (ACR) core data set and derivative “patient only” indices to assess rheumatoid arthritis", Clin Exp Rheumatol, 23(5 Suppl 39), pp.S109~S113 (2005)
53. Centola M, "Development of a multi-biomarker disease activity test for rheumatoid arthritis", PLoS One, 8, pp.e60635~ (2013)
54. Foell D, "Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial", JAMA, 303, pp.1266~1273 (2010)
55. Wittkowski H, "MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes", Ann Rheum Dis, 70, pp.2075~2081 (2011)

관련 논문AI추천